Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Liver Cirrhosis

  Free Subscription


Articles published in Dig Dis

Retrieve available abstracts of 31 articles:
HTML format
Text format



Single Articles


    September 2018
  1. GOTTLIEB A, Kottmann M, Manka P, Bedreli S, et al
    How to Define Acute Liver Failure Patients with Pre-Existing Liver Disease without Signs of Cirrhosis.
    Dig Dis. 2018 Sep 18:1-8. doi: 10.1159/000492869.
    PubMed     Text format     Abstract available


    May 2018
  2. TAJIRI K, Tokimitsu Y, Ito H, Atarashi Y, et al
    Survival Benefit of Tolvaptan for Refractory Ascites in Patients with Advanced Cirrhosis.
    Dig Dis. 2018 May 31:1-8. doi: 10.1159/000489258.
    PubMed     Text format     Abstract available


    January 2018
  3. HUANG XW, Liao B, Huang Y, Liang JY, et al
    Non-Invasive Diagnostic Criteria for Hepatocellular Carcinoma in Hepatitis B Virus-Endemic Areas: Is Cirrhosis Indispensable?
    Dig Dis. 2018 Jan 19. pii: 000486196. doi: 10.1159/000486196.
    PubMed     Text format     Abstract available


  4. BAI L, Jin W, Kong M, Zhang X, et al
    Injury Resistance in the Setting of Liver Fibrosis Is Accompanied by the Inhibition of High-Mobility Group Box-1 Translocation and Release.
    Dig Dis. 2018;36:167-176.
    PubMed     Text format     Abstract available


  5. PAN X, Han Y, Zou T, Zhu G, et al
    Sarcopenia Contributes to the Progression of Nonalcoholic Fatty Liver Disease- Related Fibrosis: A Meta-Analysis.
    Dig Dis. 2018;36:427-436.
    PubMed     Text format     Abstract available


    November 2017
  6. SHI L, Zhang X, Li J, Bai X, et al
    Favorable Effects of Endoscopic Ligation Combined with Drugs on Rebleeding and Mortality in Cirrhotic Patients: A Network Meta-Analysis.
    Dig Dis. 2017 Nov 21. doi: 10.1159/000484082.
    PubMed     Text format     Abstract available


    March 2017
  7. DI PASCOLI M, Ceranto E, De Nardi P, Donato D, et al
    Hospitalizations Due to Cirrhosis: Clinical Aspects in a Large Cohort of Italian Patients and Cost Analysis Report.
    Dig Dis. 2017 Mar 1. doi: 10.1159/000458722.
    PubMed     Text format     Abstract available


    January 2017
  8. POSE E, Cardenas A
    Translating Our Current Understanding of Ascites Management into New Therapies for Patients with Cirrhosis and Fluid Retention.
    Dig Dis. 2017;35:402-410.
    PubMed     Text format     Abstract available


  9. HEGADE VS, Jones DE, Hirschfield GM
    Apical Sodium-Dependent Transporter Inhibitors in Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.
    Dig Dis. 2017;35:267-274.
    PubMed     Text format     Abstract available


  10. WONG LL, Hegade VS, Jones DEJ
    What Comes after Ursodeoxycholic Acid in Primary Biliary Cholangitis?
    Dig Dis. 2017;35:359-366.
    PubMed     Text format     Abstract available


  11. IREDALE JP, Pellicoro A, Fallowfield JA
    Liver Fibrosis: Understanding the Dynamics of Bidirectional Wound Repair to Inform the Design of Markers and Therapies.
    Dig Dis. 2017;35:310-313.
    PubMed     Text format     Abstract available


  12. KOBAYASHI N, Kumada T, Toyoda H, Tada T, et al
    Ability of Cytokeratin-18 Fragments and FIB-4 Index to Diagnose Overall and Mild Fibrosis Nonalcoholic Steatohepatitis in Japanese Nonalcoholic Fatty Liver Disease Patients.
    Dig Dis. 2017;35:521-530.
    PubMed     Text format     Abstract available


  13. YADA N, Tamaki N, Koizumi Y, Hirooka M, et al
    Diagnosis of Fibrosis and Activity by a Combined Use of Strain and Shear Wave Imaging in Patients with Liver Disease.
    Dig Dis. 2017;35:515-520.
    PubMed     Text format     Abstract available


    June 2016
  14. FITZ JG
    Hepatology after Hepatitis C.
    Dig Dis. 2016;34:603-606.
    PubMed     Text format     Abstract available


    January 2016
  15. CHISHINA H, Hagiwara S, Nishida N, Ueshima K, et al
    Clinical Factors Predicting the Effect of Tolvaptan for Refractory Ascites in Patients with Decompensated Liver Cirrhosis.
    Dig Dis. 2016;34:659-664.
    PubMed     Text format     Abstract available


  16. SCORLETTI E, Byrne CD
    Extrahepatic Diseases and NAFLD: The Triangular Relationship between NAFLD, Type 2-Diabetes and Dysbiosis.
    Dig Dis. 2016;34 Suppl 1:11-8.
    PubMed     Text format     Abstract available


  17. MAHLI A, Hellerbrand C
    Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:32-9.
    PubMed     Text format     Abstract available


  18. DE ALWIS NM, Anstee QM, Day CP
    How to Diagnose Nonalcoholic Fatty Liver Disease.
    Dig Dis. 2016;34 Suppl 1:19-26.
    PubMed     Text format     Abstract available


  19. YADA N, Sakurai T, Minami T, Arizumi T, et al
    Prospective Risk Analysis of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C by Ultrasound Strain Elastography.
    Dig Dis. 2016;34:650-653.
    PubMed     Text format     Abstract available


  20. WU T, Wang P, Zhang T, Zheng J, et al
    Comparison of Two-Dimensional Shear Wave Elastography and Real-Time Tissue Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B.
    Dig Dis. 2016;34:640-649.
    PubMed     Text format     Abstract available


  21. NISHIDA N, Kono M, Minami T, Chishina H, et al
    Safety, Tolerability, and Efficacy of Sofosbuvir Plus Ribavirin in Elderly Patients Infected with Hepatitis C Virus Genotype 2.
    Dig Dis. 2016;34:632-639.
    PubMed     Text format     Abstract available


  22. SUGIMOTO K, Kim SK, Kim SR, Kobayashi M, et al
    Efficacy and Safety of Sofosbuvir Plus Ribavirin Treatment for Patients with Chronic Hepatitis C Genotype 2.
    Dig Dis. 2016;34:627-631.
    PubMed     Text format     Abstract available


  23. HAGIWARA S, Nishida N, Watanabe T, Sakurai T, et al
    Outcome of Asunaprevir/Daclatasvir Combination Therapy for Chronic Liver Disease Type C.
    Dig Dis. 2016;34:620-626.
    PubMed     Text format     Abstract available


  24. GALLE PR
    Extended Abstract: Management of Liver Cancer.
    Dig Dis. 2016;34:438-9.
    PubMed     Text format     Abstract available


  25. WEISKIRCHEN R, Tacke F
    Liver Fibrosis: From Pathogenesis to Novel Therapies.
    Dig Dis. 2016;34:410-22.
    PubMed     Text format     Abstract available


  26. CHAZOUILLERES O
    Novel Aspects in the Management of Cholestatic Liver Diseases.
    Dig Dis. 2016;34:340-6.
    PubMed     Text format     Abstract available


  27. WEILER-NORMANN C, Lohse AW
    Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management.
    Dig Dis. 2016;34:334-9.
    PubMed     Text format     Abstract available


  28. ARNDTZ K, Hirschfield GM
    The Pathogenesis of Autoimmune Liver Disease.
    Dig Dis. 2016;34:327-33.
    PubMed     Text format     Abstract available


  29. DALTON HR, Webb GW, Norton BC, Woolson KL, et al
    Hepatitis E Virus: Time to Change the Textbooks.
    Dig Dis. 2016;34:308-16.
    PubMed     Text format     Abstract available


  30. BLUM HE
    History and Global Burden of Viral Hepatitis.
    Dig Dis. 2016;34:293-302.
    PubMed     Text format     Abstract available


  31. KOYAMA Y, Xu J, Liu X, Brenner DA, et al
    New Developments on the Treatment of Liver Fibrosis.
    Dig Dis. 2016;34:589-96.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Cirrhosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: